Rapport Therapeutics Inc (RAPP) saw downtrend of -0.19% in the recent trading with $26.81 being its most recent. The current price level -36.57% lower than the highest price of $42.27 marked by the stock while trading over the past 52-weeks, whereas it is 316.95% higher than the lowest price of $6.43 the company dropped to over past 52-weeks. The latest news story on RAPP appeared in (GlobeNewswire) under the title “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Rapport Therapeutics Inc Earnings – What Happened With RAPP
Coming around sales and income figures on RAPP Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Rapport Therapeutics Inc (RAPP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 18.57% for net revenue.
RAPP – Rapport Therapeutics Inc Stock Earnings Estimates
The perspective of Rapport Therapeutics Inc (NASDAQ:RAPP),s current quarter earnings identifies that analysts are in consensus over the estimate of -0.7 for stock,s EPS in the current quarter. Rapport Therapeutics Inc (RAPP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 18.57% for net revenue. Company,s EPS for the last quarter was -0.57.
Rapport Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 47.65 million. RAPP does have institutional investors; and they hold 68.49% of the stock.
As on 2024-06-30, FMR LLC was the top most holder in Rapport Therapeutics Inc (NASDAQ:RAPP) with an ownership of 4.98 million shares of the company or 13.6245 of the stake worth $115.91 million. The filing also reveals ARCH VENTURE MANAGEMENT, LLC as the second largest holder in the company with a control over 10.1944 of the outstanding shares. Its stake is worth $86.73 million for having 3.73 million shares in hand.
CORMORANT ASSET MANAGEMENT, LP also came holding a key position in the company during the recent quarter and it now holds 8.0387 of the outstanding shares. With this there are now 177.0 institutions which have possession in RAPP,s shares.
Key Metrics for RAPP
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Rapport Therapeutics Inc has a debt to equity ratio of 0.02.
